FDA OK’s Merck’s new hepatitis C drug

January 29, 2016 12:46 AM

32 0

FDA OK’s Merck’s new hepatitis C drug

$54,600-per-regimen Zepatier to compete with Gilead, AbbVie treatments

The U.S. Food and Drug Administration approved Merck & Co.’s new treatment for hepatitis C, the latest entrant in a booming market for drugs for the viral infection — a market now dominated by Gilead Sciences Inc.

Read more

To category page

Loading...